Anaphylaxis

 
Underutilization of Guideline-Recommended Epinephrine in Anaphylaxis Management: New Study
March 26, 2025

A 5-year study conducted in Germany showed only 7% of adults and 8% of children with severe anaphylaxis received epinephrine.

Omlyclo Gains FDA Approval as Interchangeable Omalizumab Biosimilar: Daily Dose
March 24, 2025

Your daily dose of the clinical news you may have missed.

Antibiotics, NSAIDs Reported Most Common Cause of Pediatric Anaphylaxis
March 18, 2025

Among pediatric patients aged 1 month to 18 years with emergent anaphylaxis, cephalosporins were the leading antibiotics and ibuprofen the top NSAID implicated in a new study.

Epinephrine Nasal Spray Shows Rapid Symptom Relief in Children: Daily Dose
March 17, 2025

Your daily dose of the clinical news you may have missed.

FDA Approves Neffy 1 mg Epinephrine Nasal Spray: Daily Dose
March 13, 2025

Your daily dose of the clinical news you may have missed.

FDA Approves Omlyclo as First Interchangeable Omalizumab Biosimilar
March 10, 2025

Omlyclo is indicated for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria.

FDA Approves Neffy 1 mg Epinephrine Nasal Spray, Only Needle-Free Treatment for Patients Weighing Less Than 30 kg
March 06, 2025

The FDA approval of neffy 1 mg follows the earlier approval of the 5 mg version in August 2024.

Epinephrine Nasal Spray Shows Rapid Symptom Relief in Pediatric Anaphylaxis Study
March 03, 2025

Participants (aged 6 to 17 years) receiving neffy vs standard treatments had fewer skin, gastrointestinal, and respiratory symptoms at 15, 5, and 5 minutes, respectively.

New neffy (epinephrine nasal spray) Data To Be Shared in 9 Presentations at 2025 AAAAI
February 26, 2025

Data on the epinephrine nasal spray will include findings from an efficacy study comparing anaphylaxis symptoms during oral food challenge, according to ARS.

Neffy Update: FDA to Review 1 mg Version in First Quarter 2025, for Young Children with Type 1 Allergic Reactions
January 14, 2025

If approved, neffy 1 mg will be the only needle-free epinephrine treatment available for the younger, school-aged population.